510 related articles for article (PubMed ID: 26675306)
1. Molecular profiling of childhood cancer: Biomarkers and novel therapies.
Saletta F; Wadham C; Ziegler DS; Marshall GM; Haber M; McCowage G; Norris MD; Byrne JA
BBA Clin; 2014 Jun; 1():59-77. PubMed ID: 26675306
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.
van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT
Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.
Tang G; Li S; Zhang C; Chen H; Wang N; Feng Y
Acta Pharm Sin B; 2021 Sep; 11(9):2749-2767. PubMed ID: 34589395
[TBL] [Abstract][Full Text] [Related]
4. Biologic therapy in head and neck cancer: a road with hurdles.
Specenier P; Vermorken JB
ISRN Oncol; 2012; 2012():163752. PubMed ID: 22745915
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
6. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
Barrett D; Brown VI; Grupp SA; Teachey DT
Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of resistance to EGFR tyrosine kinase inhibitors.
Huang L; Fu L
Acta Pharm Sin B; 2015 Sep; 5(5):390-401. PubMed ID: 26579470
[TBL] [Abstract][Full Text] [Related]
8. Molecularly targeted therapies for recurrent glioblastoma: current and future targets.
Lau D; Magill ST; Aghi MK
Neurosurg Focus; 2014 Dec; 37(6):E15. PubMed ID: 25434384
[TBL] [Abstract][Full Text] [Related]
9. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
10. Molecularly targeted therapy for gastrointestinal cancer.
Wiedmann MW; Caca K
Curr Cancer Drug Targets; 2005 May; 5(3):171-93. PubMed ID: 15892618
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Investigation Demonstrates IGFR/VEGFR Receptor Cross Talk and Potential of Combined Inhibition in Pediatric Central Nervous System Atypical Teratoid Rhabdoid Tumors.
Obaid H; Kannappan S; Gupta M; Ruan Y; Zhang C; Bose P; Narendran A
Curr Cancer Drug Targets; 2020; 20(4):295-305. PubMed ID: 31713485
[TBL] [Abstract][Full Text] [Related]
12. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.
Goss GD; Spaans JN
Oncologist; 2016 Feb; 21(2):205-13. PubMed ID: 26768483
[TBL] [Abstract][Full Text] [Related]
13. Novel therapeutic targets in non-small cell lung cancer.
Janku F; Garrido-Laguna I; Petruzelka LB; Stewart DJ; Kurzrock R
J Thorac Oncol; 2011 Sep; 6(9):1601-12. PubMed ID: 21849857
[TBL] [Abstract][Full Text] [Related]
14. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapies for non-small cell lung cancer: an evolving landscape.
Pal SK; Figlin RA; Reckamp K
Mol Cancer Ther; 2010 Jul; 9(7):1931-44. PubMed ID: 20571071
[TBL] [Abstract][Full Text] [Related]
16. Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.
Bourdeanu L; Luu T
J Adv Pract Oncol; 2014; 5(4):246-60. PubMed ID: 26110069
[TBL] [Abstract][Full Text] [Related]
17. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
18. Promising molecular targeted therapies in breast cancer.
Munagala R; Aqil F; Gupta RC
Indian J Pharmacol; 2011 May; 43(3):236-45. PubMed ID: 21713084
[TBL] [Abstract][Full Text] [Related]
19. Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.
Hu K; Lee C; Qiu D; Fotovati A; Davies A; Abu-Ali S; Wai D; Lawlor ER; Triche TJ; Pallen CJ; Dunn SE
Mol Cancer Ther; 2009 Nov; 8(11):3024-35. PubMed ID: 19887553
[TBL] [Abstract][Full Text] [Related]
20. VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
Watanabe H; Ichihara E; Kayatani H; Makimoto G; Ninomiya K; Nishii K; Higo H; Ando C; Okawa S; Nakasuka T; Kano H; Hara N; Hirabae A; Kato Y; Ninomiya T; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
Cancer Sci; 2021 May; 112(5):1853-1864. PubMed ID: 33410241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
